Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Ho Chi Minh City plans to pilot mechanisms for pharmaceutical companies to adopt digital technologies, showcasing its ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced. "We ...

The latest health news includes Robert F. Kennedy Jr.'s nomination, Abbott's strategy amid global challenges, and Purdue Pharma's opioid settlement. It highlights company strategies, profits, and ...

The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...